Cargando…
Predictive markers of clinical outcome in the GRMD dog model of Duchenne muscular dystrophy
In the translational process of developing innovative therapies for DMD (Duchenne muscular dystrophy), the last preclinical validation step is often carried out in the most relevant animal model of this human disease, namely the GRMD (Golden Retriever muscular dystrophy) dog. The disease in GRMD dog...
Autores principales: | Barthélémy, Inès, Pinto-Mariz, Fernanda, Yada, Erica, Desquilbet, Loïc, Savino, Wilson, Silva-Barbosa, Suse Dayse, Faussat, Anne-Marie, Mouly, Vincent, Voit, Thomas, Blot, Stéphane, Butler-Browne, Gillian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Company of Biologists Limited
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4213729/ https://www.ncbi.nlm.nih.gov/pubmed/25261568 http://dx.doi.org/10.1242/dmm.016014 |
Ejemplares similares
-
Effects of an Immunosuppressive Treatment in the GRMD Dog Model of Duchenne Muscular Dystrophy
por: Barthélémy, Inès, et al.
Publicado: (2012) -
CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy
por: Pinto-Mariz, Fernanda, et al.
Publicado: (2015) -
Oxidative damage to urinary proteins from the GRMD dog and mdx mouse as biomarkers of dystropathology in Duchenne muscular dystrophy
por: Terrill, Jessica R., et al.
Publicado: (2020) -
T cell biology in neuromuscular disorders: a focus on Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis
por: Lemos, Julia Pereira, et al.
Publicado: (2023) -
Nitric Oxide (NO) and Duchenne Muscular Dystrophy: NO Way to Go?
por: Timpani, Cara A., et al.
Publicado: (2020)